GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California. Show more
1525 O’Brien Drive, Menlo Park, CA, 94025, United States
Start AI Chat
Market Cap
1.677B
52 Wk Range
$20.44 - $118.84
Previous Close
$43.03
Open
$42.71
Volume
3,463,050
Day Range
$42.47 - $52.00
Enterprise Value
1.793B
Cash
540.1M
Avg Qtr Burn
-63.25M
Insider Ownership
4.48%
Institutional Own.
75.32%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
